Navigation Links
Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat
Date:12/8/2011

HAYWARD, Calif., Dec. 8, 2011 /PRNewswire/ -- Metabolex today announced positive results from its clinical study of arhalofenate in combination with febuxostat (Uloric™, Takeda Pharmaceutical Company Limited). A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid (sUA). In the US, the goal of treatment is to reduce sUA levels to below 6 mg/dL. However, patients with severe tophaceous gout would benefit from reducing their sUA values below 5 or even 4 mg/dL because this would result in more rapid dissolution of their UA crystal deposits. Most patients treated with currently marketed xanthine oxidase inhibitors (allopurinol or febuxostat) alone do not reach these goals. Arhalofenate, Metabolex's lead product candidate for the treatment of hyperuricemia and gout, is a uricosuric agent that could provide additional sUA lowering when used in combination with xanthine oxidase inhibitors and be a treatment option for patients with tophaceous gout.

Clinical Study of Combination of Arhalofenate and Febuxostat

This study was an open label clinical pharmacology study on a single cohort of 11 gout patients with sUA levels of at least 8 mg/dL (mean of 9.1 mg/dL). The primary goal of the study was to assess the response rate (percentage of patients reaching goal) for the sUA targets of 5 and 4 mg/dL when treated in combination with the highest dose (80 mg) of febuxostat approved in the US and two doses (400 and 600 mg) of arhalofenate. The patients were either treatment naive or had discontinued uric acid lowering therapies for a period prior to entering the study. All patients received colchicine throughout the study for flare prophylaxis. After a two week run-in period for sUA stabilization, all 11 patients received febuxostat (80 mg) for one week. Subsequently, patients were administered 400 mg of arhalofenate for two weeks followed by up-titration of arhalo
'/>"/>

SOURCE Metabolex
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Two Metabolex Projects Recognized in Windhovers Top 10 Lists for Partnering Opportunities
2. Metabolex Announces Positive Results From Phase 1a Clinical Trial of MBX-2982
3. Metabolex Announces Election of Kurt von Emster to Board of Directors
4. Metabolex Initiates Phase 2 Trial of Arhalofenate
5. Metabolex Appoints Raymond Urbanski M.D., Ph.D. to Position of Chief Medical Officer
6. Metabolex Gout Program Recognized in Windhovers Top 10 Most Interesting Projects to Watch
7. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
8. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
9. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
10. Anesiva Announces Second Quarter 2008 Financial Results and Update
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 19, 2014 The “Human Insulin ... Intermediate Acting, Premixed), Modern Human Insulin (Rapid Acting, ... NovoRapid, Novomix, Tresiba, Others) - Forecast to 2018” ... restraints, challenges, opportunities, current market trends, and strategies ... the estimates and forecasts of the revenue and ...
(Date:10/18/2014)... October 18, 2014 The Asia-Pacific hardware ... market in Asia-Pacific with analysis and forecast of revenue. ... is expected to reach $51,362.6 million by 2018, at ... Browse through the TOC of the Asia-Pacific hardware encryption ... analysis provided. This also provides a glimpse of the ...
(Date:10/18/2014)... According to a new market research report ... Global Trends & Forecasts up till 2017”, hydraulic fracturing ... This value is expected to increase from $40 billion ... CAGR during the same period. North America is expected ... terms of hydraulic horse power supplied by the year ...
(Date:10/17/2014)... journey through the looking-glass to Wonderland, mirrors in the ... ways, including a new class of mirror that works ... The Optical Society,s (OSA) new high-impact journal ... time, a new type of mirror that forgoes a ... by using an unusual magnetic property of a non-metallic ...
Breaking Biology Technology:Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 2Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 3Hydraulic Fracturing Market Projected To Reach $64 Billion by 2017 - New Report by MarketsandMarkets 4Magnetic mirrors enable new technologies by reflecting light in uncanny ways 2Magnetic mirrors enable new technologies by reflecting light in uncanny ways 3Magnetic mirrors enable new technologies by reflecting light in uncanny ways 4
... April 4 /PRNewswire-FirstCall/ - ProMetic Life Sciences ... Rohwer, Pathogen,Removal and Diagnostics Technology Inc.,s ("PRDT") ... Research Scientist will present at,the American Chemical ... from April 6 - 10, 2008. Drs ...
... /Xinhua-PRNewswire-FirstCall/ -- WuXi,PharmaTech (Cayman) Inc. (NYSE: ... and medical device research and development,outsourcing company ... States, today,announced that it has filed a ... and Exchange Commission for a proposed follow-on ...
... FRANCISCO, Calif., and SINGAPORE, April 4, 2008 /PRNewswire/,-- ... on the,discovery and development of monoclonal antibody therapeutics ... today announced a,collaboration to advance the discovery of ... of the agreement, Raven will license its proprietary,whole ...
Cached Biology Technology:Prometic to present at the American Chemical Society 2Prometic to present at the American Chemical Society 3Prometic to present at the American Chemical Society 4WuXi PharmaTech (Cayman) Inc. Announces Filing of Registration Statement For Follow-On and Secondary Offering 2Raven biotechnologies and Bioprocessing Technology Institute Announce Collaboration to Advance Discovery of Stem Cell Antibodies 2
(Date:10/15/2014)... assess the pandemic risk from strains of influenza virus ... allow ourselves to become complacent that the most substantial ... scientists. , Influenza pandemics arise when a new virus ... widespread immunity – spreads in the human population. There ... years, the worst of which – the 1918 Spanish ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
(Date:10/14/2014)... N.C. – Like discriminating thieves, prostate cancer tumors scavenge ... the body. But such avarice may be a fatal ... a way to kill prostate cancer cells by delivering ... selectively destroys the diseased cells brimming with the mineral, ... uses two drugs already commercially available for other uses, ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... the University Hospital and the Center for Applied Medical ... an article in Nature Cancer Reviews , one ... cancer studies. The article, written by Ignacio Melero and ... States and Great Britain, addresses the use of a ...
... This week's BMJ investigates a bitter row over a ... scrutiny once again. , The dispute has pitted a ... Cha, a fertility specialist and one of the most ... writes journalist Jonathan Gornall. It is also threatening to ...
... are obese don’t really know they are overweight, researchers have ... published by Cell Press. These findings in obese mice show ... critical fat hormone—causing a cascade of events that keeps energy ... metabolic pathway remains ready to respond. , “Obesity is not ...
Cached Biology News:Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2Row over study puts Korea's scientific community under scrutiny again 2In obesity, brain becomes 'unaware' of fat 2In obesity, brain becomes 'unaware' of fat 3
... system from Molecular Devices provides precise dispensing ... The system handles a variety of plate ... and 1536-welland is the first to handle ... optimized to dispense from four different channels ...
... ProteinPilot Software enables you to ... Now you can distinguish protein isoforms, ... You can also visualize peptide-protein associations ... ideal for protein identification and relative ...
... ( Abpromise for all tested ... Synthetic peptide: VEEESFGPQPISRLE conjugated to KLH, ... 15-29 of Human Rad51 ... Swiss Protein ID: ...
Rabbit polyclonal to Esa1 ( Abpromise for all tested applications)....
Biology Products: